Edition:
United Kingdom

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

73.66EUR
12:57pm BST
Change (% chg)

€-2.53 (-3.32%)
Prev Close
€76.19
Open
€74.85
Day's High
€75.13
Day's Low
€73.17
Volume
1,176,816
Avg. Vol
3,203,603
52-wk High
€101.10
52-wk Low
€66.44

SASY.PA

Chart for SASY.PA

About

Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging... (more)

Overall

Beta: 0.77
Market Cap(Mil.): €99,760.80
Shares Outstanding(Mil.): 1,309.40
Dividend: 2.93
Yield (%): 3.85

Financials

  SASY.PA Industry Sector
P/E (TTM): 22.78 34.65 45.83
EPS (TTM): 3.34 -- --
ROI: 5.35 12.84 12.35
ROE: 7.73 13.64 13.35
Search Stocks

BRIEF-Sanofi purchase of Medivation can be accomodated under current rating-Moody's

* Says Sanofi's proposed acquisition of U.S. cancer drug company Medivation can be accomodated under its current debt rating

1:01pm BST

Sanofi confident it can win Medivation shareholders support

PARIS Sanofi , which reported higher quarterly profit on Friday boosted by its Genzyme division, is confident Medivation shareholders will back its proposed takeover of the U.S. cancer drug company.

12:02pm BST

AstraZeneca cuts costs and doubles down on cancer drugs

LONDON AstraZeneca is to cut costs by $1 billion and increase its focus on cancer treatments after underlying earnings, hit by drug patent expiries, fell 12 percent in the first quarter, broadly in line with analyst expectations.

11:15am BST

Sanofi launches $9.3 billion fight for U.S. cancer firm Medivation

LONDON/PARIS French drugmaker Sanofi went public with a $9.3 billion offer to buy Medivation on Thursday, setting up what could be a lengthy takeover battle after the U.S. cancer firm rebuffed its approaches.

9:52am BST

BRIEF-Zealand Pharma Lyxumia royalty revenue for Q1 2016 up 3 pct

* Zealand reports Lyxumia royalty revenue for Q1 2016 andmsubmission by Sanofi of the fixed-ratio combination of insulin glargine (Lantus) and lixisenatide for European registration

6:46am BST

BRIEF-Medivation confirms receipt of unsolicited proposal from Sanofi

* Medivation confirms receipt of unsolicited proposal from Sanofi

28 Apr 2016

France's Sanofi makes $9.3 bln bid for U.S. biotech Medivation

PARIS, April 28 French pharmaceuticals group Sanofi said on Thursday it had made an all-cash offer to buy U.S. biotech firm Medivation in a deal worth about $9.3 billion.

28 Apr 2016

UK agency backs cancer drug after Sanofi cuts price

LONDON Britain's healthcare cost watchdog NICE said on Friday it had changed its mind and decided to recommend Sanofi's prostate cancer drug Jevtana after the French company agreed to a further discount.

22 Apr 2016

UK agency backs cancer drug after Sanofi cuts price

LONDON, April 22 Britain's healthcare cost watchdog NICE said on Friday it had changed its mind and decided to recommend Sanofi's prostate cancer drug Jevtana after the French company agreed to a further discount.

22 Apr 2016

Sanofi invests 300 mln eur to expand Belgian plant

PARIS, April 19 Sanofi said on Tuesday that it would invest 300 million euros ($339 million) to expand a Belgian site specialised in making treatments for rare diseases.

19 Apr 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters ONE
£0.00
Provider : Thomson Reuters ONE
£0.00
Provider : Thomson Reuters ONE
£0.00
Provider : Thomson Reuters ONE
£0.00
Provider : Finlabo SIM Spa
£7.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks